Oncolytics Biotech Inc. (NASDAQ:ONCY) · earnings preview
Quarter
Q3
EPS estimate to actual
-$0.07
At a glance
Key takeaways
01Oncolytics Biotech will report Q3 2026 earnings on November 11 after market close, with analysts expecting a loss of $0.07 per share versus breakeven in the prior year.
02The company trades at $0.39 per share with a market capitalization of $100.1 million.
03Recent quarterly results show mixed performance, with Q2 missing estimates by 14.3% but Q1 beating by 14.3%, indicating inconsistent execution.
04Investors should focus on revenue trends, margin changes, and forward guidance rather than isolated quarterly results to assess whether the business is improving or deteriorating.
Earnings Results
Oncolytics Biotech Inc. (NASDAQ:ONCY) is scheduled to report its Q3 earnings results on November 11, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.07, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at , down from a year ago.
Company Overview
The stock currently trades at $0.39 with a market capitalization of $100.1M.
Ahead of Oncolytics Biotech Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Oncolytics Biotech Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.